2023 Q2 Form 10-Q Financial Statement

#000121390023038731 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $322.4K $271.6K $309.6K
YoY Change -6.32% -12.27%
Cost Of Revenue $59.16K $80.02K $68.18K
YoY Change -13.86% 17.38%
Gross Profit $263.3K $191.6K $241.5K
YoY Change -4.44% -20.64%
Gross Profit Margin 81.65% 70.54% 77.98%
Selling, General & Admin $2.690M $2.872M
YoY Change -2.07%
% of Gross Profit 1021.99% 1498.83%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.502K $3.414K $99.45K
YoY Change -98.27% -96.57%
% of Gross Profit 1.33% 1.78% 41.19%
Operating Expenses $2.690M $2.872M $3.773M
YoY Change -2.07% -23.88%
Operating Profit -$2.427M -$2.680M -$3.532M
YoY Change -1.8% -24.1%
Interest Expense $114.8K $103.8K $50.56K
YoY Change 68.41% 105.28%
% of Operating Profit
Other Income/Expense, Net -$431.2K -$274.1K -$335.6K
YoY Change 0.59% -18.33%
Pretax Income -$2.858M -$2.954M -$3.867M
YoY Change -1.45% -23.6%
Income Tax $2.025K -$223.0K
% Of Pretax Income
Net Earnings -$2.860M -$2.954M -$3.644M
YoY Change -24.53% -18.92% 793.44%
Net Earnings / Revenue -887.18% -1087.63% -1176.91%
Basic Earnings Per Share -$0.07 -$0.07 -$0.10
Diluted Earnings Per Share -$0.07 -$0.07 -$0.10
COMMON SHARES
Basic Shares Outstanding 40.22M shares 40.17M shares 36.21M shares
Diluted Shares Outstanding 40.12M shares 39.94M shares 36.21M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $319.5K $594.5K
YoY Change -80.68%
Cash & Equivalents $197.1K $221.7K $345.1K
Short-Term Investments $122.4K $372.8K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $426.5K $582.6K
Other Receivables $200.0K $200.0K
Total Short-Term Assets $946.0K $1.377M
YoY Change -58.21%
LONG-TERM ASSETS
Property, Plant & Equipment $69.08K $53.03K
YoY Change 621.71%
Goodwill $815.5K $815.5K
YoY Change -77.57%
Intangibles $2.250K $2.500K
YoY Change -99.87%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.193M $1.194M
YoY Change -79.14%
TOTAL ASSETS
Total Short-Term Assets $946.0K $1.377M
Total Long-Term Assets $1.193M $1.194M
Total Assets $2.139M $2.571M
YoY Change -73.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.113M $893.5K
YoY Change -28.66%
Accrued Expenses $545.1K $603.0K
YoY Change 759.42%
Deferred Revenue
YoY Change
Short-Term Debt $1.088M $138.9K
YoY Change 540.49%
Long-Term Debt Due $3.338M $5.300K
YoY Change 62888.68%
Total Short-Term Liabilities $6.154M $1.709M
YoY Change 242.05%
LONG-TERM LIABILITIES
Long-Term Debt $4.080K $3.050M
YoY Change -99.81%
Other Long-Term Liabilities $4.083K $265.7K
YoY Change -98.71%
Total Long-Term Liabilities $4.083K $3.316M
YoY Change -99.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.154M $1.709M
Total Long-Term Liabilities $4.083K $3.316M
Total Liabilities $6.406M $5.025M
YoY Change 48.86%
SHAREHOLDERS EQUITY
Retained Earnings -$24.85M -$21.99M
YoY Change 57.84%
Common Stock $39.97K $40.22K
YoY Change 2.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.266M -$2.452M
YoY Change
Total Liabilities & Shareholders Equity $2.139M $2.571M
YoY Change -73.2%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$2.860M -$2.954M -$3.644M
YoY Change -24.53% -18.92% 793.44%
Depreciation, Depletion And Amortization $3.502K $3.414K $99.45K
YoY Change -98.27% -96.57%
Cash From Operating Activities -$1.038M -$1.252M -$767.1K
YoY Change 2345.78% 63.18%
INVESTING ACTIVITIES
Capital Expenditures $19.55K $0.00
YoY Change -901.23%
Acquisitions -$9.000K
YoY Change
Other Investing Activities $222.7K $0.00
YoY Change -87.47%
Cash From Investing Activities $203.2K $0.00 $856.2K
YoY Change -88.55% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 810.8K $722.4K -$4.851K
YoY Change -184.74% -14991.94%
NET CHANGE
Cash From Operating Activities -1.038M -$1.252M -$767.1K
Cash From Investing Activities 203.2K 0.000 $856.2K
Cash From Financing Activities 810.8K $722.4K -$4.851K
Net Change In Cash -24.55K -$529.3K $84.23K
YoY Change -103.17% -728.44%
FREE CASH FLOW
Cash From Operating Activities -$1.038M -$1.252M -$767.1K
Capital Expenditures $19.55K $0.00
Free Cash Flow -$1.058M -$1.252M
YoY Change 2543.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
581802 usd
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1 ohcs Weighted Average Remaining Term Options Cancelled
WeightedAverageRemainingTermOptionsCancelled
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
138707 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
140060 usd
CY2023Q1 ohcs Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
200 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41210
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0181535
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1400 Old Country Road
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 306
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Westbury
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11590
CY2023Q1 dei City Area Code
CityAreaCode
(516)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
806-4201
CY2023Q1 dei Security12b Title
Security12bTitle
None
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40217598 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221679 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
751017 usd
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
582588 usd
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
525064 usd
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
200000 usd
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
200689 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
117899 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
104877 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
254919 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
144199 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1377085 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1725846 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
322866 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
339614 usd
CY2022Q4 ohcs Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
200 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
shares
CY2023Q1 ohcs Weighted Average Exercise Price Issued
WeightedAverageExercisePriceIssued
CY2023Q1 ohcs Weighted Average Remaining Term Issued
WeightedAverageRemainingTermIssued
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
5304 usd
CY2023Q1 ohcs Weighted Average Average Exercise Price Exercised
WeightedAverageAverageExercisePriceExercised
CY2023Q1 ohcs Weighted Average Remaining Term Exercised
WeightedAverageRemainingTermExercised
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2023Q1 ohcs Weighted Average Average Exercise Price Expired
WeightedAverageAverageExercisePriceExpired
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
5304 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
68382 usd
CY2023Q1 ohcs Weighted Average Remaining Term Expired
WeightedAverageRemainingTermExpired
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67052 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1709108 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1532813 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
265650 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
283092 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53032 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56196 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2500 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2750 usd
CY2023Q1 us-gaap Goodwill
Goodwill
815500 usd
CY2022Q4 us-gaap Goodwill
Goodwill
815500 usd
CY2023Q1 us-gaap Assets
Assets
2570983 usd
CY2022Q4 us-gaap Assets
Assets
2939906 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
893508 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
738395 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
603007 usd
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3044946 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2759961 usd
CY2023Q1 us-gaap Program Rights Obligations Noncurrent
ProgramRightsObligationsNoncurrent
5323 usd
CY2022Q4 us-gaap Program Rights Obligations Noncurrent
ProgramRightsObligationsNoncurrent
6562 usd
CY2023Q1 us-gaap Liabilities
Liabilities
5025027 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4582428 usd
CY2023Q1 ohcs Preferred Stock Value1
PreferredStockValue1
2 usd
CY2022Q4 ohcs Preferred Stock Value1
PreferredStockValue1
2 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
8106 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
8106 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40217598 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40217598 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38286598 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38286598 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
40218 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
38287 usd
CY2022Q4 us-gaap Preferred Stock Shares Subscribed But Unissued Value
PreferredStockSharesSubscribedButUnissuedValue
1206 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19485889 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17343671 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21986607 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19032561 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2452392 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1641289 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-1652 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-1233 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2454044 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1642522 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2570983 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2939906 usd
CY2023Q1 us-gaap Revenues
Revenues
271642 usd
CY2022Q1 us-gaap Revenues
Revenues
309629 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
80024 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
68177 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
191618 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
241452 usd
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1417943 usd
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2481510 usd
CY2023Q1 ohcs Personnel Expenses
PersonnelExpenses
886256 usd
CY2022Q1 ohcs Personnel Expenses
PersonnelExpenses
457536 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
426553 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
647450 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
141279 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
186467 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2872031 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3772963 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2680413 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3531511 usd
CY2023Q1 ohcs Amortization Of Financing Cost
AmortizationOfFinancingCost
284985 usd
CY2022Q1 ohcs Amortization Of Financing Cost
AmortizationOfFinancingCost
271232 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
103788 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
50559 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
110721 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-13765 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-274052 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-335556 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2954465 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3867067 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-223009 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2954465 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3644058 usd
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-419 usd
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-44 usd
CY2023Q1 ohcs Net Income Loss Available To Common Stockholder Basic1
NetIncomeLossAvailableToCommonStockholderBasic1
-2954046 usd
CY2022Q1 ohcs Net Income Loss Available To Common Stockholder Basic1
NetIncomeLossAvailableToCommonStockholderBasic1
-3644014 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2954465 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3644058 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39935677 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36213656 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1642522 usd
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
725000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
206755 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
1211188 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2954465 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2454044 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5412484 usd
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
467500 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
2481510 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3644058 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4717436 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2954465 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3644058 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3414 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
99452 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1417943 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2481510 usd
CY2023Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
110721 usd
CY2022Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-13765 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
284985 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
271232 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
636 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1137 usd
CY2022Q1 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
-223009 usd
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
56834 usd
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
52789 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
13022 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3345 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
155113 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
158570 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
21205 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
130441 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1251746 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-767094 usd
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-9000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
681464 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2203666 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
681464 usd
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1353666 usd
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2825 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
856175 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
725000 usd
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
-1239 usd
CY2022Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
-1226 usd
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1353 usd
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
3625 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
722408 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4851 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-529338 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
84230 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
751017 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
260838 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
221679 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
345068 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
200700 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
49500 usd
CY2022Q1 ohcs Common Stock Issued For Business Combination
CommonStockIssuedForBusinessCombination
467500 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dedicated to: (1) advancing access to clinical trial research; and (2) improving and simplifying access to vaccines and pharmaceutical products. Currently the Company provides these services through its portfolio companies, Clinical Research Alliance, Inc. (CRA), and Worker’s Health Rx (d/b/a Vitality Rx).</p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"> </p>
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span style="text-decoration:underline">Reclassification</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts included in prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s previously reported financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"> </p>
CY2023Q1 us-gaap Revenue Recognition Allowances
RevenueRecognitionAllowances
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “<i>Revenue from contracts with customers,”</i> (Topic 606). Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. The Company’s main revenue stream is from services. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery.  For services performed by CRA, the Company’s performance obligations are generally met at the point in time the services are rendered.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in certificates of deposit, deposit accounts or treasury bills. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"> </p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221679 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
751017 usd
CY2023Q1 us-gaap Related Parties Amount In Cost Of Sales
RelatedPartiesAmountInCostOfSales
0 usd
CY2022 us-gaap Related Parties Amount In Cost Of Sales
RelatedPartiesAmountInCostOfSales
363153 usd
CY2022 ohcs Accounts Receivable Percentage
AccountsReceivablePercentage
0.10 pure
CY2022Q1 ohcs Annual Revenue Percentage
AnnualRevenuePercentage
0.10 pure
CY2023Q1 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
1417943 usd
CY2022Q1 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
2481510 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1417943 usd
CY2022Q1 us-gaap Restricted Stock Expense
RestrictedStockExpense
206755 usd
CY2023Q1 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2022Q1 us-gaap Advertising Expense
AdvertisingExpense
9750 usd
CY2023Q1 ohcs Lease Agreement Commencing Description
LeaseAgreementCommencingDescription
The Company entered into a lease agreement commencing on February 1, 2021 through August 31, 2026, for 1,246 square feet of office space located at One Dupont Street, Suite 112, Plainview, New York, 11803.
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.50 pure
CY2023Q1 ohcs Warrants
Warrants
1705000 shares
CY2022Q1 ohcs Warrants
Warrants
165000 shares
CY2023Q1 ohcs Stock Options
StockOptions
1403750 shares
CY2022Q1 ohcs Stock Options
StockOptions
375000 shares
CY2023Q1 ohcs Convertible Notes Payable Shares
ConvertibleNotesPayableShares
4400000 shares
CY2022Q1 ohcs Convertible Notes Payable Shares
ConvertibleNotesPayableShares
2200000 shares
CY2023Q1 us-gaap Auction Market Preferred Securities Shares Issued
AuctionMarketPreferredSecuritiesSharesIssued
406664 shares
CY2022Q1 us-gaap Auction Market Preferred Securities Shares Issued
AuctionMarketPreferredSecuritiesSharesIssued
406664 shares
CY2023Q1 ohcs Totalshares
Totalshares
7915414 shares
CY2022Q1 ohcs Totalshares
Totalshares
3146664 shares
CY2023Q1 ohcs Office Lease
OfficeLease
456819 usd
CY2022Q4 ohcs Office Lease
OfficeLease
456819 usd
CY2023Q1 ohcs Equipment Lease
EquipmentLease
5611 usd
CY2022Q4 ohcs Equipment Lease
EquipmentLease
2063 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
139564 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
119268 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
322866 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
339614 usd
CY2023Q1 ohcs Office Lease Liability
OfficeLeaseLiability
332470 usd
CY2022Q4 ohcs Office Lease Liability
OfficeLeaseLiability
348081 usd
CY2023Q1 ohcs Equipment Lease Liability
EquipmentLeaseLiability
1562 usd
CY2022Q4 ohcs Equipment Lease Liability
EquipmentLeaseLiability
2063 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
68382 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67052 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
265650 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
283092 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
70251 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
91335 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
93837 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
88269 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
49677 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
393369 usd
CY2023Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
59337 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
334032 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221679 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
751017 usd
CY2023Q1 us-gaap Capital Units Net Amount
CapitalUnitsNetAmount
323023 usd
CY2022Q4 us-gaap Capital Units Net Amount
CapitalUnitsNetAmount
193033 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
2954465 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
3644058 usd
CY2023Q1 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
21986607 usd
CY2022Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
19032561 usd
CY2023Q1 ohcs Going Concern Term
GoingConcernTerm
P1Y
CY2020Q4 us-gaap Debtor In Possession Financing Interest Rate On Borrowings Outstanding
DebtorInPossessionFinancingInterestRateOnBorrowingsOutstanding
1 pure
CY2020Q4 ohcs Business Acquisition Percentage Of Voting Interest Acquired
BusinessAcquisitionPercentageOfVotingInterestAcquired
0.73 pure
CY2021Q3 us-gaap Memberships In Exchanges Owned
MembershipsInExchangesOwned
425000 usd
CY2023Q1 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
1
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
1.25
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
103788 usd
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
50559 usd
CY2023Q1 us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
815500 usd
CY2022Q4 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
2000000 shares
CY2022Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
400000 shares
CY2022Q4 us-gaap Loans Payable
LoansPayable
200000 usd
CY2022Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
100000 usd
CY2022Q4 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
3600000 usd
CY2022Q4 us-gaap Beneficial Interest
BeneficialInterest
100000 usd
CY2022Q4 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
3500000 usd
CY2022Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
3627927 usd
CY2022Q4 us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
127927 usd
CY2023Q1 us-gaap Notes Receivable Fair Value Disclosure
NotesReceivableFairValueDisclosure
200000 usd
CY2022Q4 us-gaap Notes Receivable Fair Value Disclosure
NotesReceivableFairValueDisclosure
200689 usd
CY2023Q1 ohcs Aggregate Principal Amount
AggregatePrincipalAmount
200000 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
284985 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
271232 usd
CY2023Q1 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
56696 usd
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
56696 usd
CY2023Q1 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
23896 usd
CY2022Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
23896 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80592 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80592 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27560 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24396 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53032 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56196 usd
CY2023Q1 us-gaap Depreciation
Depreciation
3164 usd
CY2022Q1 us-gaap Depreciation
Depreciation
300 usd
CY2023Q1 ohcs Websites
Websites
3000 usd
CY2022Q4 ohcs Websites
Websites
3000 usd
CY2023Q1 us-gaap Accumulated Amortization Of Other Deferred Costs
AccumulatedAmortizationOfOtherDeferredCosts
500 usd
CY2022Q4 us-gaap Accumulated Amortization Of Other Deferred Costs
AccumulatedAmortizationOfOtherDeferredCosts
250 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2500 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2750 usd
CY2023Q1 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
250 usd
CY2022Q1 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
99152 usd
CY2022Q2 ohcs Aggregate Purchase Price
AggregatePurchasePrice
2000000 usd
CY2023Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
368754 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
327440 usd
CY2023Q1 ohcs Gross Unrealized Loss
GrossUnrealizedLoss
-113835 usd
CY2022 ohcs Gross Unrealized Loss
GrossUnrealizedLoss
-183241 usd
CY2023Q1 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
254919 usd
CY2022 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
144199 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
110721 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-13765 usd
CY2023Q1 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
161269 usd
CY2023Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
50548 usd
CY2022Q1 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
63572 usd
CY2022Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
49807 usd
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
138707 usd
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
140060 usd
CY2023Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
250000 usd
CY2023Q1 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0164 pure
CY2023Q1 us-gaap Line Of Credit Facility Periodic Payment
LineOfCreditFacilityPeriodicPayment
1353 usd
CY2023Q1 ohcs Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
200 usd
CY2022Q4 ohcs Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
200 usd
CY2022Q2 ohcs Shares Of Common Stock
SharesOfCommonStock
1540000 shares
CY2022Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
1
CY2020Q4 ohcs Notes Payable Related Party Issued
NotesPayableRelatedPartyIssued
10100 usd
CY2023Q1 us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
200 usd
CY2022 us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
200 usd
CY2023Q1 ohcs Longterm Notes Payable Related Party
LongtermNotesPayableRelatedParty
200 usd
CY2022 ohcs Longterm Notes Payable Related Party
LongtermNotesPayableRelatedParty
200 usd
CY2022Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
362000 shares
CY2022Q3 us-gaap Other Notes Payable
OtherNotesPayable
25000 usd
CY2022Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
296839 usd
CY2022 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
218238 usd
CY2020Q2 us-gaap Loans Receivable With Fixed Rates Of Interest1
LoansReceivableWithFixedRatesOfInterest1
145683 usd
CY2021Q1 us-gaap Loans Receivable With Fixed Rates Of Interest1
LoansReceivableWithFixedRatesOfInterest1
148975 usd
CY2023Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
126546 usd
CY2020Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
126546 usd
CY2023Q1 us-gaap Loans Receivable Description Of Variable Rate Basis
LoansReceivableDescriptionOfVariableRateBasis
The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
5323 usd
CY2023Q1 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
5304 usd
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
148975 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
3044946 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
2759961 usd
CY2021Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2200000 usd
CY2021Q2 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
2200000 usd
CY2021Q2 ohcs Aggregate Purchase Price
AggregatePurchasePrice
2000000 usd
CY2021Q2 ohcs Shares Of Common Stock
SharesOfCommonStock
165000 shares
CY2021Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
1
CY2021Q2 ohcs Ownership Percentage
OwnershipPercentage
0.0999 pure
CY2021Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.10 pure
CY2021Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.25
CY2023Q1 ohcs Equity Method Investments Ownership Percentages
EquityMethodInvestmentsOwnershipPercentages
0.0999 pure
CY2022Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2200000 usd
CY2022Q2 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
2200000 usd
CY2022Q2 ohcs Equity Method Investments Ownership Percentages
EquityMethodInvestmentsOwnershipPercentages
0.0999 pure
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2481510 usd
CY2021Q3 us-gaap Demutualization By Insurance Entity Securities Issued Quantity Of Shares
DemutualizationByInsuranceEntitySecuritiesIssuedQuantityOfShares
2000000 shares
CY2021Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
1
CY2023Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4141000 shares
CY2022 ohcs Raised Pursuant Amount
RaisedPursuantAmount
1956000 usd
CY2023Q1 ohcs Raised Pursuant Amount
RaisedPursuantAmount
725000 usd
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
9998899 shares
CY2020Q4 ohcs Cancelled Shares
CancelledShares
9998889 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
250000 shares
CY2023Q1 us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
1.39
CY2023Q1 us-gaap Share Price
SharePrice
1.35
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.39
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
2.3213 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0402 pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M3D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5895000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.69
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y1M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
250000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.39
CY2023Q1 ohcs Weighted Average Remaining Term Options Granted
WeightedAverageRemainingTermOptionsGranted
P10Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6145000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.68
CY2023Q1 ohcs Weighted Average Remaining Term Options Outstanding At Ending Balance
WeightedAverageRemainingTermOptionsOutstandingAtEndingBalance
P8Y11M8D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1403750 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.7
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M18D
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1417943 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5495583 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2000000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
65000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2065000 shares
CY2023Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.25 pure
CY2023Q1 us-gaap Restricted Stock Expense
RestrictedStockExpense
206755 usd
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
3230995 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y9M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1705000 shares
CY2023Q1 ohcs Weighted Average Average Exercise Price Beginning Balance
WeightedAverageAverageExercisePriceBeginningBalance
1.25
CY2023Q1 ohcs Weighted Average Remaining Term Beginning Balance
WeightedAverageRemainingTermBeginningBalance
P4Y4M2D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1705000 shares
CY2023Q1 ohcs Weighted Average Average Exercise Price Ending Balance
WeightedAverageAverageExercisePriceEndingBalance
1.25
CY2023Q1 ohcs Weighted Average Remaining Term Ending Balance1
WeightedAverageRemainingTermEndingBalance1
P4Y1M2D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1705000 shares
CY2023Q1 ohcs Weighted Average Average Exercise Price Warrants Exercisable
WeightedAverageAverageExercisePriceWarrantsExercisable
1.25
CY2023Q1 ohcs Weighted Average Remaining Term Warrants Exercisable1
WeightedAverageRemainingTermWarrantsExercisable1
P4Y1M2D
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Optimus Healthcare Services, Inc.
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
usd
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36213656 shares
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2022Q1 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
usd
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1 ohcs Weighted Average Remaining Term Options Exercised
WeightedAverageRemainingTermOptionsExercised
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001892025

Files In Submission

Name View Source Status
ohcs-20230331_cal.xml Edgar Link unprocessable
0001213900-23-038731-index-headers.html Edgar Link pending
0001213900-23-038731-index.html Edgar Link pending
0001213900-23-038731.txt Edgar Link pending
0001213900-23-038731-xbrl.zip Edgar Link pending
f10q0323ex31-1_optimushealth.htm Edgar Link pending
f10q0323ex31-2_optimushealth.htm Edgar Link pending
f10q0323ex32-1_optimushealth.htm Edgar Link pending
f10q0323ex32-2_optimushealth.htm Edgar Link pending
f10q0323_optimushealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ohcs-20230331.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10q0323_optimushealth_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
ohcs-20230331_def.xml Edgar Link unprocessable
ohcs-20230331_pre.xml Edgar Link unprocessable
ohcs-20230331_lab.xml Edgar Link unprocessable
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending